Arab Finance: Macro Group Pharmaceutical (Macro Capital) generated consolidated net profits attributable to the parent amounting to EGP 68.911 million in the first half (H1) of 2025, against net losses of EGP 88.795 million in H1 2024, according to the financial results.

Basic and diluted earnings per share (EPS) hit EGP 0.12 in H1 2025, versus a loss per share of EGP 0.16 a year earlier.

The sales increased to EGP 411.541 million in the first six months of 2025 from EGP 155.252 million at the end of June 2024.

Macro Capital turned profitable at EGP 71.283 million in H1 2025, against standalone net losses valued at EGP 86.119 million.

Standalone revenues jumped year-on-year (YoY) to EGP 411.396 million as of June 30^th, 2025, from EGP 155.139 million.

Extracted Oils posts 251.2% YoY higher profits in FY2024/25 Updated 8/21/2025 10:35:00 AM

CI Capital’s consolidated profits hit EGP 776.97M in H1 2025 Updated 8/21/2025 9:45:00 AM

El Ahram for Printing widens losses by 800.3% YoY in H1 2025 Updated 8/20/2025 7:45:00 AM

Unipack sees 63.1% lower consolidated profits in H1 2025 Updated 8/18/2025 2:12:00 PM

Speed Medical registers 30.9% YoY lower consolidated losses in H1 2025 Updated 8/18/2025 12:57:00 PM